COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- Macao establishes 4 state key laboratories: national political adviser
- Metronome and navigator: How China's five-year plans steer unprecedented modernization
- China's new five-year plan charts world's largest modernization by population
- China's top political adviser visits press representatives
- China Coast Guard vessel Sandu conducts patrols in South China Sea
- Tree planting activities held across China
